All News
The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis
Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.
Read Article
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Read Article
#BestACR20Tweets
RT @SattuiSEMD :L06: Mavrilimumab in #GCA
Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new/relapsing/ref pts, No diff in AE
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
Disease flare 19% in tx vs. 46% in PBO at 26wk
Sustained remission 83% vs. 50% in PBO
Similar AE in both groups Abs#L06
https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna: #ACR20 prosp cohort study of angiographic lesions in Takayasu’ GCA:new angio lesions more likely in TAK.Improvement possible in both conditions, more likely in TAK.Change in the branch arteries more dynamic than in the aorta https://t.co/iC0TJ08Tsr https://t.co/Y1hIDGJ9Ro
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : @RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/M97X8fLfLp
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestARC20Tweets
"RT @drdavidliew : Great to sit down with @LCalabreseDO @Sarah_L_Mackie @RichardPAConway a few hours ago and chat about two very interesting GCA therapeutics abstracts: https://t.co/V3fzB0W3Ko
great discussion!
#ACR20 @RheumNow"
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/Ay7Sw0eMTY
Links:
Dr. John Cush RheumNow ( View Tweet)
"The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis" by Dr. Richard Conway ( @RichardPAConway)
https://t.co/VG1ah3Nq5c https://t.co/jORhfQn3EC
Links:
Dr. John Cush RheumNow ( View Tweet)
Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh #ACR20
https://t.co/kJxdgoL5EI https://t.co/uYUwUr53lL
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/HrMGvqcNC4
Links:
Dr. John Cush RheumNow ( View Tweet)
San Diego-based rheumatologist Dr. Arthur Kavanaugh takes a closer look at Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis #ACR20.
https://t.co/53gQ0dLjU7
Links:
Dr. John Cush RheumNow ( View Tweet)
Evolution of GCA Treatments - More to Come by Meral El Ramahi ( @MeralElRamahiMD) #ACR20
Reflecting on the innovative treatment approach to Giant Cell Arteritis (GCA)
https://t.co/xuQ7Litn8t https://t.co/4NtVSMOPsS
Links:
Dr. John Cush RheumNow ( View Tweet)
GCA Treatment Data: Dr. David Liew Abstract ( @drdavidliew)
Dr. David Liew reviews abstracts #0516 and #0513 presented at the #ACR20 annual meeting.
https://t.co/KmjTRmDbA1
Links:
Dr. John Cush RheumNow ( View Tweet)
Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20
https://t.co/kwXUhn8QSG https://t.co/OjTtFE6jEt
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr P Seo notes based on PEXIVAS study while PLEX does not seem to help with AAV, it showed you can drop steroid dose sooner: start pred 1 mg/kg/d but drop down after 1 week to 0.5 mg/kg/d #ACRReview #ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
And we're off! #ACR20 year in review
⭐️@philseo's #Vasculitis lecture⭐️
Take home lessons/ remaining questions from GiACTA ⬇️
#ACRambassador https://t.co/7C9QxbUeNH
Elizabeth Graef SituationRheum ( View Tweet)
📌More #Vasculitis pearls from #ACR20 Year in Review
#PEXIVAS in a nutshell ⬇️
#ACRambassador https://t.co/PnoP7QIiYs
Elizabeth Graef SituationRheum ( View Tweet)
There are a number of important mimics of IgG4-RD that should be considered
🔵ANCA-associated vasculitis
🔵Multicentric Castleman’s disease
🔵Rosai-Dorfman disease
🔵Inflammatory myofibroblastic tumour
🔵Cutaneous plasmacytosis
🔵Erdheim-Chester disease
🔵Malignancy
#ACR20
Chris Wincup chriswincup ( View Tweet)
